Literature DB >> 25680597

Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.

Carien L Creutzberg1, Ruud G P M van Stiphout2, Remi A Nout3, Ludy C H W Lutgens2, Ina M Jürgenliemk-Schulz4, Jan J Jobsen5, Vincent T H B M Smit6, Philippe Lambin2.   

Abstract

BACKGROUND: Postoperative radiation therapy for stage I endometrial cancer improves locoregional control but is without survival benefit. To facilitate treatment decision support for individual patients, accurate statistical models to predict locoregional relapse (LRR), distant relapse (DR), overall survival (OS), and disease-free survival (DFS) are required. METHODS AND MATERIALS: Clinical trial data from the randomized Post Operative Radiation Therapy for Endometrial Cancer (PORTEC-1; N=714 patients) and PORTEC-2 (N=427 patients) trials and registered group (grade 3 and deep invasion, n=99) were pooled for analysis (N=1240). For most patients (86%) pathology review data were available; otherwise original pathology data were used. Trial variables which were clinically relevant and eligible according to data constraints were age, stage, given treatment (pelvic external beam radiation therapy (EBRT), vaginal brachytherapy (VBT), or no adjuvant treatment, FIGO histological grade, depth of invasion, and lymph-vascular invasion (LVSI). Multivariate analyses were based on Cox proportional hazards regression model. Predictors were selected based on a backward elimination scheme. Model results were expressed by the c-index (0.5-1.0; random to perfect prediction). Two validation sets (n=244 and 291 patients) were used.
RESULTS: Accuracy of the developed models was good, with training accuracies between 0.71 and 0.78. The nomograms validated well for DR (0.73), DFS (0.69), and OS (0.70), but validation was only fair for LRR (0.59). Ranking of variables as to their predictive power showed that age, tumor grade, and LVSI were highly predictive for all outcomes, and given treatment for LRR and DFS. The nomograms were able to significantly distinguish low- from high-probability patients for these outcomes.
CONCLUSIONS: The nomograms are internally validated and able to accurately predict long-term outcome for endometrial cancer patients with observation, pelvic EBRT, or VBT after surgery. These models facilitate decision support in daily clinical practice and can be used for patient counseling and shared decision making, selecting patients who benefit most from adjuvant treatment, and generating new hypotheses.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25680597     DOI: 10.1016/j.ijrobp.2014.11.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.

Authors:  Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small
Journal:  Brachytherapy       Date:  2016-05-31       Impact factor: 2.362

Review 2.  Artificial intelligence for clinical oncology.

Authors:  Benjamin H Kann; Ahmed Hosny; Hugo J W L Aerts
Journal:  Cancer Cell       Date:  2021-04-29       Impact factor: 38.585

3.  Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences.

Authors:  Suwanit Therasakvichya; Sompop Kuljarusnont; Janjira Petsuksiri; Pattama Chaopotong; Vuthinun Achariyapota; Pisutt Srichaikul; Atthapon Jaishuen
Journal:  J Gynecol Oncol       Date:  2016-05-16       Impact factor: 4.401

4.  A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables.

Authors:  Erin A Salinas; Marina D Miller; Andreea M Newtson; Deepti Sharma; Megan E McDonald; Matthew E Keeney; Brian J Smith; David P Bender; Michael J Goodheart; Kristina W Thiel; Eric J Devor; Kimberly K Leslie; Jesus Gonzalez Bosquet
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

5.  Systematic lymphadenectomy for intermediate risk endometrial carcinoma treatment does not improve the oncological outcome.

Authors:  Elaine C Candido; Osmar F Rangel Neto; Maria Carolina S Toledo; José Carlos C Torres; Aurea A A Cairo; Joana F Braganca; Julio C Teixeira
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-04-18

6.  Predicting prognosis of endometrioid endometrial adenocarcinoma on the basis of gene expression and clinical features using Random Forest.

Authors:  Fufen Yin; Xingyang Shao; Lijun Zhao; Xiaoping Li; Jingyi Zhou; Yuan Cheng; Xiangjun He; Shu Lei; Jiangeng Li; Jianliu Wang
Journal:  Oncol Lett       Date:  2019-06-20       Impact factor: 2.967

7.  Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.

Authors:  Cristina Anton; Rodolpho Truffa Kleine; Eric Mayerhoff; Maria Del Pilar Esteves Diz; Daniela de Freitas; Heloisa de Andrade Carvalho; João Paulo Mancusi de Carvalho; Alexandre Silva E Silva; Maria Luiza Nogueira Dias Genta; André Lopes de Faria E Silva; Rafael Calil Salim; Andrea Aranha; Rossana Veronica Mendoza Lopez; Filomena Marino Carvalho; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

8.  Quantification of recurrence risk based on number of adverse prognostic factors in women with stage I uterine endometrioid carcinoma

Authors:  Andrew E Cook; Ibrahim Aref; Charlotte Burmeister; Miriana Hijaz; Mohamed A Elshaikh
Journal:  J Turk Ger Gynecol Assoc       Date:  2021-12-06

9.  Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.

Authors:  Nikola Cihoric; Alexandros Tsikkinis; Cristina Gutierrez Miguelez; Vratislav Strnad; Ivan Soldatovic; Pirus Ghadjar; Branislav Jeremic; Alan Dal Pra; Daniel M Aebersold; Kristina Lössl
Journal:  Radiat Oncol       Date:  2016-03-22       Impact factor: 3.481

10.  Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.

Authors:  Rainer Kimmig; Antonella Iannaccone; Bahriye Aktas; Paul Buderath; Martin Heubner
Journal:  Arch Gynecol Obstet       Date:  2015-11-23       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.